56 results about "Scleroderma disease" patented technology

Monoclonal antibodies are identified that bind the IL-21 protein. These antibodies are used to identify regions of the IL-21 protein to where binding neutralizes IL-21 activity. Hybridomas and methods of producing anti-IL-21 monoclonal antibodies are described. The monoclonal antibodies are useful in treating IL-21-mediated diseases, which may include autoimmune and inflammatory diseases such as pancreatitis, type I diabetes (IDDM), Graves Disease, inflammatory bowel disease (IBD), Crohn's Disease, ulcerative colitis, irritable bowel syndrome, multiple sclerosis, rheumatoid arthritis, diverticulosis, systemic lupus erythematosus, psoriasis, ankylosing spondylitis, scleroderma, systemic sclerosis, psoriatic arthritis, osteoarthritis, atopic dermatitis, vitiligo, graft vs. host disease (GVHD), cutaneous T cell lymphoma (CTCL), Sjogren's syndrome, glomerulonephritis, IgA nephropathy, graft versous host disease, transplant rejection, atopic dermatitis, anti-phospholipid syndrome, and asthma, and other autoimmune diseases.

Methods and compositions are provided which contains preparations of calcium chelators, bisphosphonates, antibiotics, antimicrobial agents, cytostatic agents, calcium ATPase and pyrophosphatase pump inhibitors, calcium phosphate-crystal dissolving agents, agents effective against calcium phosphate-crystal nucleation and crystal growth, and / or a combination of supportive agents and which may be used for treating and or reducing pathological calcifications, the growth of Nanobacterium and calcification-induced diseases including, but not limited to, Arteriosclerosis, Atherosclerosis, Coronary Heart Disease, Chronic Heart Failure, Valve Calcifications, Arterial Aneurysms, Calcific Aortic Stenosis, Transient Cerebral Ischemia, Stroke, Peripheral Vascular Disease, Vascular Thrombosis, Dental Plaque, Gum Disease (dental pulp stones), Salivary Gland Stones, Chronic Infection Syndromes such as Chronic Fatigue Syndrome, Kidney and Bladder Stones, Gall Stones, Pancreas and Bowel Diseases (such as Pancreatic Duct Stones, Crohn's Disease, Colitis Ulcerosa), Liver Diseases (such as Liver Cirrhosis, Liver Cysts), Testicular Microliths, Chronic Calculous Prostatitis, Prostate Calcification, Calcification in Hemodialysis Patients, Malacoplakia, Autoimmune Diseases. Erythematosus, Scleroderma, Dermatomyositis, Antiphospholipid Syndrome, Arteritis Nodosa, Thrombocytopenia, Hemolytic Anemia, Myelitis, Livedo Reticularis, Chorea, Migraine, Juvenile Dermatomyositis, Grave's Disease, Hypothyreoidism, Type 1 Diabetes Mellitus, Addison's Disease, Hypopituitarism, Placental and Fetal Disorders, Polycystic Kidney Disease, Glomerulopathies, Eye Diseases (such as Corneal Calcifications, Cataracts, Macular Degeneration and Retinal Vasculature-derived Processes and other Retinal Degenerations, Retinal Nerve Degeneration, Retinitis, and Iritis), Ear Diseases (such as Otosclerosis, Degeneration of Otoliths and Symptoms from the Vestibular Organ and Inner Ear (Vertigo and Tinnitus)), Thyroglossal Cysts, Thyroid Cysts, Ovarian Cysts, Cancer (such as Meningiomas, Breast Cancer, Prostate Cancer, Thyroid Cancer, Serous Ovarian Adenocarcinoma), Skin Diseases (such as Calcinosis Cutis, Calciphylaxis, Psoriasis, Eczema, Lichen Ruber Planus), Rheumatoid Arthritis, Calcific Tenditis, Osteoarthritis, Fibromyalgia, Bone Spurs, Diffuse Interstitial Skeletal Hyperostosis, Intracranial Calcifications (such as Degenerative Disease Processes and Dementia), Erythrocyte-Related Diseases involving Anemia, Intraerythrocytic Nanobacterial Infection and Splenic Calcifications, Chronic Obstructive Pulmonary Disease, Broncholiths, Bronchial Stones, Neuropathy, Calcification and Encrustations of Implants, Mixed Calcified Biofilms, and Myelodegenerative Disorders (such as Multiple Sclerosis, Lou Gehrig's and Alzheimer's Disease) in humans and animals. The method comprises administering the various classes of compositions of the present invention, which together effectively inhibit or treat the development of calcifications in vivo.

The present invention relates to methods useful for the treatment or prevention of disease-related wasting. The methods of the invention comprise the administration of an effective amount of a JNK Inhibitor. In one embodiment, the disease is HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease or tuberculosis. The methods can further comprise the administration of a therapeutic or prophylactic agent useful for the treatment or prevention of HIV, AIDS, cancer, end-stage renal disease, kidney failure, chronic heart disease, obstructive pulmonary disease, chronic infectious diseases (e.g., osteoarthritis and bacterial endocarditis), chronic inflammatory diseases (e.g., scleroderma and mixed connective tissue disease) or tuberculosis.

Methods for diagnosing and monitoring systemic lupus erythematosus (SLE) or scleroderma by determining, in a blood sample from the individual being diagnosed or monitored, complement component C4d deposited on surfaces of red blood cells in the sample, and optionally also determining complement receptor CR1 deposited on the red blood cell surfaces. For diagnosis this is compared with the quantity of C4d (and optionally CR1) present on red blood cells of normal individuals. For monitoring it is compared with a value in a sample or samples previously obtained from the individual patient.The comparison may be made with individual values for C4d and CR1 and / or with a ratio of the two found in normal individuals.

The invention provides a novel herbal composition containing the extracts of the leaves and / or stem of <italic>Argemone mexicana < / highlight>plant, optionally containing the extracts of the fruits of <italic>Cuminum cyminum< / highlight>, which exhibits useful in vitro, in vivo and interesting immunological and pharmacological activities; a process for preparation thereof; and a method of treatment of psoriasis and related immunological and biological disorders by administration of the said novel herbal composition. The useful in vitro, in vivo and interesting immunological and pharmacological activities exhibited by the extracts and fractions of the leaves and / or stem of <italic>Argemone mexicana < / highlight>plant include immunosuppression, lymphoproliferation inhibition, cytokine modulation such as IL-2 inhibition, IFNgamma inhibition, IL-10 induction, keratinocyte proliferation inhibition, keratolytic activity, endothelial cell proliferation inhibition, inhibition of cell adhesion molecule expression such as ICAM-1, MEST inhibition, and enzymes inhibition such as p60src Tyrosine kinase, which are known to be involved in anti-psoriatic activity. The novel herbal composition(s) is useful in the treatment of various disorders, such as psoriasis including plaque psoriasis, gutatte psoriasis, pustular psoriasis and psoriasis of the nails; dermatitis and scleroderma; eczema; inflammatory disorders and other autoimmune diseases like psoriatic arthritis, rheumatoid arthritis, Crohn's disease, multiple sclerosis, irritable bowel disease, ankylosing spondilitis, systemic lupus erythremetosus and Sjogren's syndrome; allergies like asthma and chronic obstructive pulmonary disease and is safe, well-tolerated, non-toxic, with minimal and reversible adverse reactions or side effects, and most importantly, with minimal relapse or recurrence of the disease following completion of a treatment regimen. The invention also describes the presence of phosphodiesterase (III, IV and V) inhibition and 5-Lipoxygenase inhibition in the aqueous, ethanolic or aqueous-ethanolic extracts of fruits of <italic>Cuminum cyminum < / highlight>plant.

The use of sGC stimulators, sGC activators alone, or in combination with PDE5 inhibitors for the prevention and treatment of fibrotic diseases, such as systemic sclerosis, scleroderma, and the concomitant fibrosis of internal organs.

The invention relates to the use of osteoprotegerin for treatment and / or prevention of fibrotic diseases, in particular of scleroderma.

The invention provides a micro RNA group related to Th17 differentiation. The micro RNA group comprises micro RNA 4426, micro RNA 3615, micro RNA 106b, micro RNA 590 and micro RNA 573. The micro RNA changes remarkably in the Th17 differentiation process and can be used as Th17 control targets for preparing drugs for treating or preventing Th17-related diseases including lupus erythematosus, dermatomyositis, vasculitis, sicca syndromes, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, scleroderma, multiple sclerosis, malaria, solar dermatitis, eczema, leucoderma, psoriasis, atopic dermatitis, lichen planus, diabetes, coronary heart diseases, hyperlipemia and the like. The micro RNA group is sensitive to hydroxychloroquine intervention and can serve as a sensitive index for judgment of the clinical effect of hydroxychloroquine, and the micro RNA is convenient to test clinically and can be rapidly used for judging the clinical effect of hydroxychloroquine.

The invention relates to the use of osteoprotegerin for treatment and / or prevention of fibrotic diseases, in particular of scleroderma.

This invention is in the field of medicinal chemistry and relates to novel compounds, and pharmaceutical compositions and methods of use thereof for the treatment and / or prevention of fibrotic diseases including scleroderma, systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloids, chronic kidney disease, chronic graft rejection, and other scarring / wound healing abnormalities, post operative adhesions, and reactive fibrosis. The invention also relates to methods of using the compounds and pharmaceutical compositions of this invention to treat fibrotic conditions.

Disclosed is a composition of matter of the formula (X<1>)a-(F<1>)d-(X<2>)b-(F<2>)e-(X<3>)c and multimers thereof, in which F<1> and F<2> are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X<1>, X<2>, and X<3> are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector. Methods of treating an autoimmune disorder, such as, but not limited to, multiple sclerosis, type 1 diabetes, psoriasis, inflammatory bowel disease, contact-mediated dermatitis, rheumatoid arthritis, psoriatic arthritis, asthma, allergy, restinosis, systemic sclerosis, fibrosis, scleroderma, glomerulonephritis, Sjogren syndrome, inflammatory bone resorption, transplant rejection, graft-versus-host disease, and lupus and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.

The present disclosure provides a method for treating lupus, Sjogren's syndrome or scleroderma, the method comprising administering to the mammal an immunoglobulin which binds an interleukin 3 receptor alpha (IL-3R alpha) chain and which depletes or at least partly eliminates plasmacytoid dendritic cells (p DCs) and basophils to which it binds.

A solid-phase immunoassay for 6-keto-Prostaglandin F1α, the stable hydrolysis product of prostacyclin (Prostaglandin I2) is disclosed. Prostacyclin, a potent vasodilator with anti-platelet and anti-proliferative properties is an effective treatment for primary pulmonary hypertension and pulmonary arterial hypertension associated with scleroderma and scleroderma-like syndrome. Levels of 6-keto-Prostaglandin F1α can be directly correlated with levels of prostacyclin. Therefore, 6-keto-Prostaglandin F1α has become the indicator of choice to measure prostacyclin levels. The single step immunoassay for 6-keto-Prostaglandin F1α uses the bioluminescent protein, aequorin as a label. Analyte-label conjugates were constructed by linking the carboxyl group of 6-keto-Prostaglandin F1α and lysine residues of aequorin by chemical conjugation methods. The binding properties of 6-keto-Prostaglandin F1α towards its antibody and the bioluminescent properties of aequorin are retained in the conjugate. The concentration of 6-keto-Prostaglandin F1α after extraction from plasma shows good correlation with the concentration of 6-keto-Prostaglandin F1α obtained without prior extraction of the same plasma sample. The assay allows the measurement of 6-keto-Prostaglandin F1α directly in plasma without any pre-treatment of the samples, which results in a much simpler method with a faster assay time.

Proline compounds as Granzyme B inhibitors, compositions that include the compounds, and methods for using the compounds. Methods for treating cutaneous scleroderma, epidermolysis bullosa, radiation dermatitis, alopecia areata, and discoid lupus erythematosus are provided.

The present invention relates to the field of medicine, provided herein are novel nitrogenous heterocyclic compounds, their preparation methods and their uses as drugs, especially for treatment and prevention of tissue fibrosis. Also provided herein are pharmaceutically acceptable compositions comprising the nitrogenous heterocyclic compounds and the uses of the compositions in the treatment of human or animal tissue fibrosis, especially for human or animal renal interstitial fibrosis, glomerular sclerosis, liver fibrosis, pulmonary fibrosis, peritoneal fibrosis, myocardial fibrosis, dermatofibrosis, postsurgical adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myosarcoma, neurofibroma, pulmonary interstitial fibrosis, diabetic nephropathy, alzheimer disease or vascular fibrosis.

The invention discloses a safflower scleroderma-resisting metabonomics analysis method based on liquid chromatography-tandem mass spectrometry. The safflower scleroderma-resisting metabonomics analysis method comprises the following steps: 1) dividing healthy mice into three experimental groups including a control group, a scleroderma model group and a safflower treatment group; subcutaneously injecting a bleomycin solution into the mice of the scleroderma model group and the safflower treatment group every day to replicate a mouse scleroderma model; feeding safflower water decoction into themice of the safflower treatment group every day and treating; modeling for 28 days and judging whether modeling succeeds or not by physiological changes and pathological changes; 2) after the modelingsucceeds, taking blood serum samples of the mice of the three experimental groups and detecting by adopting the liquid chromatography-tandem mass spectrometry to obtain a fingerprint spectrum of theblood serum samples of the mice of the three experimental groups; 3) analyzing the fingerprint spectrum by adopting multivariate statistics to obtain a differential metabolite; identifying to obtain abiomarker. According to the method disclosed by the invention, the biomarker of safflower scleroderma-resisting metabonomics is obtained and a safflower scleroderma-resisting multi-component and multi-target acting mechanism is analyzed and identified.

The invention discloses application of adipose-derived stem cells in preparation of products for assisting adipose transplantation in treating localized scleroderma. By constructing a bleomycin scleroderma nude mouse model and studying adipose-derived stem cell and adipose transplantation, the TGF-beta 1 content and the III type collagen content of scleroderma group mice can be reduced, and the symptoms of scleroderma are relieved.

The invention discloses a Chinese patent medicament for treating scleroderma, belonging to the technical field of traditional Chinese medicines for treating skin diseases. The Chinese patent medicament is prepared into various oral dosage forms from peach kernel, cortex dictamni, safflower, prepared rehmannia rhizome, wild celery, divaricate saposhnikovia root, yellowmouth dutchmanspipe root, szechuan lovage rhizome, Chinese angelica, tree peony root-bark, notopterygium root, rehmannia root, Chinese ephedra, garter snake, red paeony root, dried orange peel and liquoric root with the conventional pharmaceutical method. The Chinese patent medicament has the effects of tonifying the liver and the spleen, expelling wind, removing dampness, regulation of qi and blood, clearing and activating the channels and collaterals, promoting blood circulation by removing blood stasis, regulating immunologic function and improving skin microcirculation, and has the characteristics of determined curative effect and convenience for taking on the treatment and prevention of scleroderma.

Magnesium salts / complexes of compounds useful for inhibiting the ADAM-IO protein and methods of making and purifying them are provided. Further provided are compositions comprising magnesium salts / complexes of the compounds in combination with a pharmaceutically acceptable carrier. The compounds well as such compositions comprising them are useful for the treatment of cancer, arthritis, diseases related to angiogenesis, such as renal diseases, heart diseases, such as heart failure, atherosclerosis, and stroke, inflammation, ulcer, infertility, scleroderma, endometriosis, mesothelioma, and diabetes. In addition, methods of treating forms of cancer, arthritis, and diseases related to angiogenesis in which ADAM-10 plays a critical role are provided.

The invention relates to the technical field of antibody engineering, and particularly provides an anti-IL-17RA monoclonal antibody which comprises a heavy chain variable region and a light chain variable region. The anti-IL-17RA monoclonal antibody has relatively strong affinity and good biological activity, the specific binding with the IL-17RA antigen can be realized, the combination of the IL-17A and the IL-17RA is blocked, the IL-17 / IL-17R signal pathway is antagonized and blocked, the IL-17 / IL-17R signal pathway is the autoimmune disease treatment drug having the huge potential, the symptoms of the autoimmune disease are effectively relieved, the progression of the disease is prevented, and the autoimmune disease comprises but is not limited to psoriasis, rheumatoid arthritis, ankylosing spondylitis or scleroderma and the like.

The invention which belongs to the fields of gene engineering and gene diagnosis provides a method for detecting SNP of a BANK1 gene. The method comprises the following steps: 1, designing a primer and a probe for amplifying an rs10516487 site or an rs17266594 site; 2, carrying out PCR amplification by utilizing the primer and the probe with sample DNA as a template, wherein concentrations of the upstream primer and the downstream primer in the primer are different, and the concentration of one is not less than five times the concentration of other one; and 3, adding a saturated dye, analyzing a melting degree curve, and determining the SNP. The method which can detect the polymorphism of the rs10516487 site and the rs17266594 site of the BANK1 gene in peripheral blood or a body fluid can be used to determine the attack possibility of autoimmtme diseases of systemic lupus erythematosus, rheumatoid arthritis, systemic chorionitis and the like. The method has the advantages of rapidness, simplicity, no pollution, and high detection result resolution. The invention also provides a corresponding detection kit.

The present invention relates to a use of treprostinil to treat and prevent ischemic lesions. The present invention describes novel methods for using Treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and / or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease. Raynaud'sdisease, Raynaud's phenomenon and / or other conditions that cause such lesions. The invention also relates to kits for treatment and / or prevention of ischemic lesions, comprising an effective amount ofTreprostinil or its derivative, or a pharmaceutically acceptable salt thereof.

The invention provides mebendazole for use in the treatment or prophylaxis of a chronic inflammatory disease, and in particular wherein the chronic inflammatory disease is an autoimmune disease, for example sarcoidosis, systemic lupus erythematosus (SLE), Huntington's disease, end stage renal disease, systemic sclerosis (also called scleroderma), myositis, diabetes type 1, multiple sclerosis, Sjögren's syndrome, rheumatoid arthritis, psoriasis, primary biliary cirrhosis, autoimmune hepatitis, Graves' disease, Addison's disease, tuberculosis, Crohn's disease, ulcerative colitis, inflammatory bowel disease, Alzheimer's disease and coeliac disease. A method for the treatment or prophylaxis of a chronic inflammatory disease, comprising administering an effective amount of a mebendazole or a pharmaceutical composition of mebendazole is also provided. The use of mebendazole for the manufacture of a medicament for the treatment of a chronic inflammatory disease is also provided.

The present invention is related to the use of benzazole derivatives of formula (I) for the treatment and / or prevention of scleroderma and its therapeutic implications selected in the group consisting of systemic sclerosis, scleroderma-like disorders, sine scleroderma, liver cirrhosis, interstitial pulmonary fibrosis, Dupuytren's contracture, keloid and other scarring / wound healing abnormalities, postoperative adhesions and reactive fibrosis, as well as chronic heart failure, in particular after myocardial infarction.

The invention relates to the technical field of antibody engineering, and particularly provides an anti-IL-17RA monoclonal antibody which comprises a heavy chain variable region and a light chain variable region. The anti-IL-17RA monoclonal antibody has relatively strong affinity and good biological activity, the specific binding with the IL-17RA antigen can be realized, the combination of the IL-17A and the IL-17RA is blocked, the IL-17 / IL-17R signal pathway is antagonized and blocked, the IL-17 / IL-17R signal pathway is the autoimmune disease treatment drug having the huge potential, the symptoms of the autoimmune disease are effectively relieved, the progression of the disease is prevented, and the autoimmune disease comprises but is not limited to psoriasis, rheumatoid arthritis, ankylosing spondylitis or scleroderma and the like.

The invention provides a rehabilitation physiotherapy system for preventing hand and foot limb necrosis of a scleroderma patient based on big data. The rehabilitation physiotherapy system comprises a database module, a diagnosis acquisition module, a processing module and a physiotherapy module, the database module stores symptom data of scleroderma patients; the diagnosis acquisition module is used for acquiring illness state data of a patient; the processing module is used for processing according to the acquired illness state data to obtain a corresponding physiotherapy scheme; according to the system and the method, scleroderma of the patient is detected and analyzed in time, so that a set of targeted physiotherapy rehabilitation scheme is matched, and the problems that existing scleroderma patient detection is not convenient enough, and rehabilitation pertinence is insufficient are solved.

The invention discloses an immunomodulatory active protein WG-SP01, and the protein WG-SP01 can activate the activity of LDH and ACP, so that macrophages of an organism are in an activated state; the ATP activity of lymphocytes can be obviously improved; the multiplication capacity of T lymphocytes and B lymphocytes of the spleen is obviously improved; the protein WG-SP01 has a remarkable immune regulation effect. Therefore, the protein WG-SP01 can be used as an active ingredient of an immunomodulator or an immunopotentiator for preparing medicines or functional foods for treating immune diseases such as systemic lupus erythematosus, rheumatoid arthritis, scleroderma and hyperthyroidism, and also can be used for other pharmaceuticals or functional foods with an immunoregulation effect.